Parent Application No.: 09/915,152

Preliminary Amendment Dated: January 27, 2004

## **AMENDMENTS TO THE CLAIMS**

Please amend the claims as follows:

## **Listing of Claims:**

1. (Original) A method of making a composition for the treatment or prevention of a disease selected from the group consisting of non-insulin dependent diabetes mellitus, syndrome X, hyperlipidaemia, hypertension, hyperinsulinaemia, hypercholesterinaemia, hypertriglycerinaemia, impaired glucose tolerance and related

obesity comprising combining phytanic acid or a phytanic acid derivative with a

pharmaceutically acceptable carrier.

2. (Currently amended) A composition for the treatment or prevention of

non-insulin dependent diabetes mellitus comprising phytanic acid or a derivative

thereof.

3. (Original) A composition according to claim 2 further comprising a

pharmaceutically acceptable carrier.

4. (Original) A composition according to claim 3 wherein the

pharmaceutically acceptable carrier is selected from the group consisting of diluent,

filler, disintegrate, wetting agent, lubricant, colorant, flavorant, adjuvants, and

combinations thereof.

5. (Currently amended) A composition according to claim 4 wherein the

carrier is selected from the group consisting of microcrystalline icrocrystalline cellulose,

starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone,

magnesium stearate, sodium lauryl sulfate, sucrose, and combinations thereof.

Parent Application No.: 09/915,152

Preliminary Amendment Dated: January 27, 2004

6. (Original) A composition according to claim 2 comprising from about 0.1 to about 1000 mg of phytanic acid or a derivative thereof.

7. (Original) A composition according to claim 6 comprising from about 0.1 to about 500 mg of phytanic acid or a derivative thereof.

8. (Original) A composition according to claim 7 comprising from about 0.1 to about 100 mg of phytanic acid or a derivative thereof.

9. (Original) A dietary supplement comprising a composition according to claim 2.

10. (Original) A method of treating or preventing non-insulin dependent diabetes mellitus comprising administering to a human or an animal an effective dose of a pharmaceutical composition or a dietary supplement comprising phytanic acid, a phytanic acid precursor, or a derivative of phytanic acid.

11. (Original) A method according to claim 10 wherein the phytanic acid derivative, or phytanic acid precursor is derived from phytanic acid.

- 12. (Original) A method according to claim 10 wherein the phytanic acid derivative or phytanic acid precursor is derived from phytenic acid.
- 13. (Original) A method according to claim 10 wherein the phytanic acid derivative or phytanic acid precursor is selected from the group consisting of phytol, hydroxy-phytanic acid, phytanic esters, phytanic amides, hydroxy-phytanic esters.

Parent Application No.: 09/915,152

Preliminary Amendment Dated: January 27, 2004

hydroxy-phytanic amides, hydroxy-phytenic acid, phytenic esters, phytenic amides, hydroxy-phytenic esters, hydroxy-phytenic amides, and combinations thereof.

14. (Original) A method for increasing cellular glucose uptake comprising administering to an animal or a human in need of increased cellular glucose uptake a

phytanic acid derivative or a phytanic acid precursor in an effective amount to increase

cellular glucose uptake.

15. (Original) A method according to claim 14 wherein the effective

amount of the phytanic acid derivative or phytanic acid precursor induces a gene

selected from the group consisting of GLUT-1, GLUT-2, GLUT-4, glucokinase, and

combinations thereof to increase cellular glucose activity within the animal or human.

16. (Original) A method according to claim 14 wherein the effective

amount of the phytanic acid derivative or phytanic acid precursor is from about 0.1 to

about 50 mg/kg body weight/day.

17. (Original) A method according to claim 16 wherein the effective

amount of the phytanic acid derivative or phytanic acid precursor is from about 0.5 to

about 40 mg/kg body weight/day.

18. A method according to claim 17 wherein the effective amount of the

phytanic acid derivative or phytanic acid precursor is from about 1.0 to about 20 mg/kg

body weight/day.

6

Parent Application No.: 09/915,152 Preliminary Amendment Dated: January 27, 2004

19. (Original) A method of reducing plasma insulin comprising administering to a mammal a plasma insulin reducing amount of a composition comprising phytanic acid or a derivative thereof.